Viracta Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Viracta Therapeutics

03/05/2024 12:49

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show
no change in quarterly revenue when it reports  results on May 6
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Viracta Therapeutics Inc
is
for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $5.50​, above​ its last closing price
of $0.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.34       -0.31      -0.35     Missed  -12.9
 Sep. 30 2023  -0.30       -0.30      -0.33     Missed  -8.2
 Jun. 30 2023  -0.30       -0.29      -0.32     Missed  -10.3​
 Mar. 31 2023  -0.31       -0.31      -0.32     Missed  -2.4
 ​​Dec.        -0.33       -0.38      -0.27     Beat    29.9
 31 2022                                                
 Sep. 30 2022  -0.30       -0.30      -0.47     Missed  -54.1​
 Jun. 30 2022  -0.30       -0.30      -0.28     Beat    5.9
 Mar. 31 2022  -0.31       -0.31      -0.28     Beat    11.1
 This summary was machine generated May 3 at 11:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)